Tissue Level vs Bone Level Implants for Plural Restorations : a Multicentre Randomised Controlled Trial (IBERICA)

Anthogyr Axiom Tissue-Level implants and corresponding Multi-Unit abutments recently enriched the available product range for dental surgeons. This Post-Market Clinical Follow-Up study aims at confirming the safety and performance of these products. The comparison with similar Anthogyr Axiom Bone-level implants will provide additional information on the effect of platform-switching in bone level maintenance for single and two-piece design at the implant level.

Study Overview

• Status: Active, not recruiting
• Conditions: Edentulous; Dental Implants
• Intervention / Treatment: Device: Axiom TL REG; Device: Axiom BL REG

Detailed Description

This is a multicenter, comparative, prospective, randomized, controlled, post-market clinical follow-up (PMCF) study.

The total study duration for each patient should be 3 years. Anthogyr Axiom TL and BL REG and corresponding Multi-Unit abutments will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.

In total 8 visits per patient are scheduled in this study

Implant and prosthesis survival, success, bone level changes, patient reported outcome, soft tissue assessment and adverse events (AEs) will be assessed.

The investigational devices are CE-(Conformité Européenne, meaning European Conformity) marked product.

3 centers will participate in Spain and Portugal.

The study and any amendments will be performed as far as possible according to International Organization for Standardization (ISO) 14155 and conform to the Declaration of Helsinki (last revision Fortaleza 2013) and local legal and regulatory requirements.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Portugal
  • Porto, Portugal
    • Faculdade De Medicina Dentaria da Universidade do Porto
• Spain
  • Barcelona, Spain
    • Universidad International de Catalunya
  • Santiago De Compostela, Spain
    • Universidad de Santiago de Compostela

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Patients must have voluntarily signed the Informed Consent Form before any study related procedures are performed, are willing and able to attend scheduled follow-up visits and agree that the pseudonymized data are collected and analyzed.
• Patients must be males or females who are a minimum of 18 years of age.
• Patients with a minimum of 4 weeks history of edentulism in the study area, in need of a multiple teeth replacement with dental implants
• Patients with complete soft tissue coverage of the socket at implant placement

Exclusion Criteria:

- Patients with inadequate bone volume and/or quality: Only minor and simultaneous bone augmentation procedures will be allowed where required for regeneration of minor defects. Insufficient bone volume and quality is defined as secondary exclusion criterion and the patient will be considered as screening failure.

• Uncontrolled systemic disease that would interfere with dental implant therapy (e.g. uncontrolled diabetes)
• Any contraindications for oral surgical procedures
• History of local irradiation therapy in the head / neck area
• Patients who are currently heavy smokers (defined >10 cigarettes per day or >1 cigar per day), or have ≥ 20 pack years who use chewing tobacco
• Medical conditions requiring chronic high dose steroid therapy or high dose anti-resorptive treatment
• Subjects who have undergone administration of any investigational device within 30 days of enrolment in the study
• Conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability
• Cognitive impairment that would interfere with the ability to perform adequate oral hygiene (assessed by Ottawa 3DY scale)
• Patients with chronic pain

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Study Group; Anthogyr Axiom TL REG and corresponding Multi-Unit abutments	Device: Axiom TL REG; Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional. In each case, the MU abutment will be placed immediately after implant placement. Multi-Unit abutments are used to fix the prosthesis; Other Names: Multi-Unit abutment
Active Comparator: Control Group; Anthogyr Axiom BL REG and corresponding Multi-Unit abutment	Device: Axiom BL REG; Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional. In each case, the MU abutment will be placed immediately after implant placement. Multi-Unit abutments are used to fix the prosthesis; Other Names: Multi-Unit abutment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Marginal Bone Level Change	Change in crestal bone level measured by analysis of standardized peri-apical xrays [mm].	6 months,12 months, and 3 years after loading

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Implant survival	A surviving implant is an implant that is in place at the time of evaluation.	6 months,12 months, and 3 years after loading
Prosthesis Survival	a surviving prosthesis is a prosthesis that is not broken at the time of evaluation.	6 months,12 months, and 3 years after prosthesis placement
14 item Oral Health Impact Profile (OHIP-14)	he local language version of the OPHIP-14 is a self-reported questionnaire that measures dysfunction, discomfort and disability attributed to oral conditions. The questionnaire focuses on seven dimensions of impact: Functional limitation; Pain; Psychological discomfort; Physical disability; Psychological disability; Social disability; Handicap. The patients will be asked to respond according to frequency of impact on a 5-point Likert scale coded never (score 0), hardly ever (score 1), occasionally (score 2), fairly often (score 3) and very often (score 4).	screening visit, 6, 12 months and 3 years after loading

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events	Adverse Events will be recorded at every visit. Adverse Events will be recorded at every visit.	3 years after inclusion
Device Deficiencies	Adverse Events will be recorded at every visit. Any device complications and deficiencies will be recorded as Device Deficiencies.	3 years after inclusion

Collaborators and Investigators

• Sponsor: Anthogyr
• Investigators: Principal Investigator: Juan Blanco Carrión, Pr.Dr., Universidad de Santiago de Compostela

Study record dates

Study Major Dates

• Study Start (Actual): March 30, 2022
• Primary Completion (Estimated): July 18, 2025
• Study Completion (Estimated): July 18, 2027

Study Registration Dates

• First Submitted: January 21, 2022
• First Submitted That Met QC Criteria: February 1, 2022
• First Posted (Actual): February 4, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 17, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: implant; dental; Anthogyr
• Additional Relevant MeSH Terms: Mouth Diseases; Stomatognathic Diseases; Tooth Diseases; Mouth, Edentulous
• Other Study ID Numbers: C1902

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No